Forging a potent vaccine adjuvant: CpG ODN/cationic peptide nanorings
Date
2014-07
Authors
Gungor, B.
Yagci, F. C.
Gursel, I.
Gursel, M.
Editor(s)
Advisor
Supervisor
Co-Advisor
Co-Supervisor
Instructor
Source Title
Oncolmmunology
Print ISSN
Electronic ISSN
2162-402X
Publisher
Taylor & Francis Inc.
Volume
3
Issue
7
Pages
950166-1 - 950166-3
Language
English
Type
Journal Title
Journal ISSN
Volume Title
Series
Abstract
Type I interferon inducers may potentially be engineered to function as antiviral and anticancer agents, or alternatively, vaccine adjuvants, all of which may have clinical applications. We recently described a simple strategy to convert a Toll-like receptor 9 (TLR9) agonist devoid of interferon alpha (IFN alpha) stimulating activity into a robust Type I interferon inducer with potent vaccine adjuvant activity.